Wang Xiaowei, Zhu Yingying, Ni Daofeng, Lv Wei, Gao Zhiqiang, Qi Fang
Department of Otolaryngology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P.R. China.
Exp Ther Med. 2017 Nov;14(5):3971-3978. doi: 10.3892/etm.2017.5042. Epub 2017 Aug 28.
The aim of the present study was to investigate the effect of glucocorticoid intervention on olfactory dysfunction in mice with allergic rhinitis (AR). An AR animal model was established by intraperitoneal injection and intranasal application of ovalbumin to mice. The olfactory function of the mice was evaluated using a buried food test, and morphological changes in the nasal mucosa were determined using hematoxylin and eosin staining. The expression of olfactory marker protein (OMP) in the olfactory mucosa was tested by immunohistochemistry, and was observed on days 7 and 14 after the application of glucocorticoid. The incidence rate of olfactory dysfunction in AR mice was 75.34%, and the olfactory epithelium became thinner in mice with AR compared to the control group. In addition, the expression of OMP in the olfactory epithelium was downregulated in mice with AR compared with the control group. Expression of OMP in the olfactory epithelium was upregulated in the budesonide group A and betamethasone group A compared with the medicine-free group, whereas the expression of OMP in the olfactory epithelium of budesonide group A or betamethasone group A was not significantly different from the control group. Moreover, the expression of OMP in the budesonide group B was similar to budesonide group A, and expression of OMP in betamethasone group B was similar to betamethasone group A. The expression of OMP in olfactory mucosa is downregulated in AR mice with olfactory dysfunction. Following the application of glucocorticoid, the expression of OMP in the olfactory mucosa in mice is upregulated. Moreover, intranasal local glucocorticoid has a low incidence of systemic adverse reactions, and is recommended for the treatment of olfactory dysfunction in AR.
本研究的目的是探讨糖皮质激素干预对变应性鼻炎（AR）小鼠嗅觉功能障碍的影响。通过腹腔注射和鼻内给予小鼠卵清蛋白建立AR动物模型。采用埋食试验评估小鼠的嗅觉功能，并用苏木精和伊红染色确定鼻黏膜的形态学变化。通过免疫组织化学检测嗅觉黏膜中嗅觉标记蛋白（OMP）的表达，并在给予糖皮质激素后的第7天和第14天进行观察。AR小鼠嗅觉功能障碍的发生率为75.34%，与对照组相比，AR小鼠的嗅觉上皮变薄。此外，与对照组相比，AR小鼠嗅觉上皮中OMP的表达下调。与未用药组相比，布地奈德A组和倍他米松A组嗅觉上皮中OMP的表达上调，而布地奈德A组或倍他米松A组嗅觉上皮中OMP的表达与对照组无显著差异。此外，布地奈德B组中OMP的表达与布地奈德A组相似，倍他米松B组中OMP的表达与倍他米松A组相似。嗅觉功能障碍的AR小鼠嗅觉黏膜中OMP的表达下调。应用糖皮质激素后，小鼠嗅觉黏膜中OMP的表达上调。此外，鼻内局部应用糖皮质激素全身不良反应的发生率较低，推荐用于治疗AR患者的嗅觉功能障碍。
